(Q34414702)

2 August 2017

title

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma (English)

1 reference

2 August 2017

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Dolors Colomer

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Gaël Roué

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

A Moros

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

V Rodríguez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

I Saborit-Villarroya

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

A Montraveta

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

P Balsas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

P Sandy

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

A Martínez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

A Wiestner

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

E Normant

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

P Pérez-Galán

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

18 March 2014

1 reference

2 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

2049-2059

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24721791%20AND%20SRC:MED&resulttype=core&format=json

The complex landscape of genetic alterations in mantle cell lymphoma

13 June 2020

cites work

1 reference

12 December 2020

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

1 reference

12 December 2020

Selective inhibition of tumor oncogenes by disruption of super-enhancers

1 reference

12 December 2020

IRF4 is a suppressor of c-Myc induced B cell leukemia.

1 reference

12 December 2020

Inhibition of BET bromodomain targets genetically diverse glioblastoma

1 reference

12 December 2020

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

1 reference

12 December 2020

Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma

1 reference

12 December 2020

Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function

1 reference

12 December 2020

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

1 reference

12 December 2020

The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability

1 reference

12 December 2020

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

1 reference

12 December 2020

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia

1 reference

12 December 2020

Molecular pathogenesis of mantle cell lymphoma

1 reference

12 December 2020

BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain

1 reference

12 December 2020

Proteasome inhibitors in cancer therapy: lessons from the first decade

1 reference

12 December 2020

IRF4 addiction in multiple myeloma

1 reference

12 December 2020

The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78

1 reference

12 December 2020

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

1 reference

12 December 2020

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

1 reference

12 December 2020

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

1 reference

12 December 2020

Characterization of MYC translocations in multiple myeloma cell lines

1 reference

12 December 2020

Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas

1 reference

12 December 2020

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

1 reference

12 December 2020

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

1 reference

12 December 2020

Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity

1 reference

12 December 2020

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Targeting MYC dependence in cancer by inhibiting BET bromodomains

1 reference

12 December 2020

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

1 reference

12 December 2020

Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma

1 reference

12 December 2020

In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization

1 reference

12 December 2020

Targeting the ubiquitin proteasome system: beyond proteasome inhibition.

1 reference

12 December 2020

Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation

1 reference

12 December 2020

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

12 December 2020

BET bromodomain inhibition rescues erythropoietin differentiation of human erythroleukemia cell line UT7.

1 reference

12 December 2020

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

1 reference

12 December 2020

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

1 reference

12 December 2020

Cancer: An unexpected addiction.

1 reference

12 December 2020

A library of gene expression signatures to illuminate normal and pathological lymphoid biology

1 reference

12 December 2020

Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma

1 reference

12 December 2020